Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JUNIOR STRENGTH ADVIL vs MOTRIN MIGRAINE PAIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Reversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby alleviating pain and inflammation.
FDA-labeled: Temporary relief of minor aches and pains (e.g., headache, toothache, menstrual cramps, muscle aches, backache),Fever reduction,Off-label: Osteoarthritis, rheumatoid arthritis (in higher doses),Off-label: Patent ductus arteriosus closure in neonates
Migraine headache pain relief (OTC),Primary dysmenorrhea,Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Fever reduction
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.
Ibuprofen 400 mg orally every 4-6 hours as needed, maximum 1200 mg in 24 hours.
2-4 hours (terminal); prolonged in hepatic impairment and elderly.
2 hours (1.5-2.5 h in adults; prolonged in elderly and renal impairment).
Hepatic metabolism primarily via CYP2C9; also involves glucuronidation; major metabolites are hydroxylated and carboxylated forms.
Primarily hepatic via CYP2C9; metabolites undergo glucuronidation and renal excretion.
Primarily renal (90% as glucuronide conjugates and 10% unchanged); <5% biliary/fecal.
Renal: 90% (metabolites and unchanged, 10-20% unchanged). Biliary/Fecal: <5%.
90-99% bound to albumin; concentration-dependent.
99% bound to albumin.
0.1-0.2 L/kg (low, consistent with high protein binding).
0.1-0.2 L/kg. Clinical meaning: Low Vd indicates limited tissue distribution, primarily in plasma.
Oral: 85-95% (ibuprofen susp/liquid); 80-100% (tablets/capsules).
Oral: 80-100% (absolute bioavailability).
e GFR 30-60 m L/min: reduce dose by 50% or extend interval to q8-12h; e GFR <30 m L/min: avoid use.
e GFR 30-59 m L/min: No adjustment; e GFR 15-29 m L/min: Reduce dose to 200 mg every 6-8 hours, maximum 600 mg/day; e GFR <15 m L/min: Avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: avoid use.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Use with caution, reduce dose by 50%; Child-Pugh Class C: Avoid use.
5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day (or 1200 mg/day) for children ≥6 months.
Children weighing ≥50 kg: Same as adult; <50 kg: 7.5-10 mg/kg per dose every 6-8 hours, maximum 30 mg/kg/day.
Start at lowest effective dose (200 mg q6-8h); maximum 1200 mg/day; monitor renal function and GI bleeding risk.
Start at lowest effective dose (200 mg every 6-8 hours), monitor renal function and gastrointestinal bleeding risk; maximum 600 mg/day.
No FDA boxed warning for JUNIOR STRENGTH ADVIL (ibuprofen). However, NSAIDs in general carry a boxed warning for cardiovascular thrombotic events and gastrointestinal bleeding.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time without warning symptoms. Elderly patients and those with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
Cardiovascular risk: Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke,Gastrointestinal risk: Increased risk of GI bleeding, ulceration, and perforation,Renal effects: May cause renal impairment, especially in patients with pre-existing renal disease,Hypersensitivity reactions: Anaphylaxis, bronchospasm,Fluid retention and edema,Avoid use with other NSAIDs or in late pregnancy (risk of premature closure of ductus arteriosus)
Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke; risk of serious GI adverse events; avoid in setting of coronary artery bypass graft (CABG) surgery; renal toxicity; anaphylactoid reactions; severe skin reactions (e.g., Stevens-Johnson syndrome); may blunt the antihypertensive effect of ACE inhibitors; avoid late pregnancy due to risk of premature closure of ductus arteriosus.
Hypersensitivity to ibuprofen or any component of the formulation,Asthma, urticaria, or allergic-type reactions after aspirin or other NSAID use,Treatment of perioperative pain in coronary artery bypass graft (CABG) surgery,Use in children with chickenpox (due to increased risk of severe skin reactions)
Known hypersensitivity to ibuprofen or any component of the formulation; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; late pregnancy (third trimester).
Avoid alcohol: increases risk of GI bleeding. Limit caffeine as may increase side effects. Can be taken with food or milk to minimize GI irritation.
Avoid alcohol and caffeine-containing foods/drinks (coffee, tea, cola, chocolate) due to additive caffeine effects. Grapefruit juice may increase ibuprofen absorption; consider avoidance. No other significant dietary restrictions.
Avoid during third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal dysfunction. First and second trimester use only if clearly needed; limited human data suggest low risk of major malformations but increased risk of miscarriage and cardiac defects.
First trimester: Risk of spontaneous abortion and congenital malformations (cardiac, gastroschisis). Second trimester: Avoid due to possible oligohydramnios and fetal renal impairment. Third trimester: Contraindicated after 30 weeks gestation due to risk of premature closure of ductus arteriosus and persistent pulmonary hypertension. NSAID use after 20 weeks may cause oligohydramnios from fetal renal dysfunction.
Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01). Not expected to cause adverse effects in infants with short-term use at recommended doses. Avoid in nursing mothers breastfeeding preterm or low-birth-weight infants.
Ibuprofen is excreted into breast milk in low amounts (M/P ratio approximately 0.6-1.0). Peak infant dose is less than 1% of maternal weight-adjusted dose. Considered compatible with breastfeeding; use lowest effective dose for shortest duration.
No specific dose adjustment recommended in pregnancy. However, use lowest effective dose for shortest duration. In third trimester, avoid use unless benefit outweighs risk of fetal toxicity.
No standard pharmacokinetic data mandating dose adjustment in pregnancy. However, increased renal clearance and volume of distribution may require higher doses for efficacy; use lowest effective dose and avoid third trimester. No specific dosage adjustment recommended in product labeling.
For pediatric patients, weight-based dosing is critical; typical dose is 5-10 mg/kg/dose every 6-8 hours. Avoid use in children with dehydration, bleeding disorders, or aspirin allergy. May mask signs of infection. Not recommended for children under 6 months.
Motrin Migraine Pain contains ibuprofen 200 mg and caffeine 65 mg per tablet. Caffeine enhances analgesic effect and may help with migraine-associated fatigue. Absorb more rapidly on empty stomach; take at first sign of migraine. Avoid in patients with aspirin allergy, peptic ulcer disease, or uncontrolled hypertension.
Give with food or milk to reduce stomach upset.,Do not exceed recommended dose; overdose can cause liver damage or gastrointestinal bleeding.,Do not use with other products containing ibuprofen or NSAIDs.,Shake suspension well before measuring dose using appropriate dosing device.,Stop use and consult doctor if symptoms worsen or new symptoms occur.,Keep out of reach of children; in case of overdose, contact Poison Control immediately.
Take with food or milk if stomach upset occurs.,Do not exceed 2 tablets in 24 hours unless directed by a doctor.,Avoid other caffeine-containing products while taking this medication.,Seek medical attention if migraine is severe or accompanied by stiff neck, speech changes, or vision loss.,Do not use for more than 10 days for headache or 3 days for fever.,Discontinue and contact doctor if rash, swelling, or breathing difficulty occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JUNIOR STRENGTH ADVIL vs MOTRIN MIGRAINE PAIN, answered by our medical review team.
JUNIOR STRENGTH ADVIL is a NSAID Analgesic that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. MOTRIN MIGRAINE PAIN is a NSAID Analgesic that works by Reversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby alleviating pain and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JUNIOR STRENGTH ADVIL and MOTRIN MIGRAINE PAIN depend on the specific clinical indication. These are both NSAID Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JUNIOR STRENGTH ADVIL is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.. The standard adult dose of MOTRIN MIGRAINE PAIN is: Ibuprofen 400 mg orally every 4-6 hours as needed, maximum 1200 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JUNIOR STRENGTH ADVIL and MOTRIN MIGRAINE PAIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JUNIOR STRENGTH ADVIL is classified as Category C. Avoid during third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal dysfunction. First and second trimester use only if clearly nee. MOTRIN MIGRAINE PAIN is classified as Category C. First trimester: Risk of spontaneous abortion and congenital malformations (cardiac, gastroschisis). Second trimester: Avoid due to possible oligohydramnios and fetal renal impairm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.